Psychopharmacology & Cognitive Neuroscience · · 24 min read · By

Dihexa for SSRI & Antidepressant Brain Fog: Emotional Blunting, Memory & the 2026 UK Review

“My mood is better on my antidepressant — so why do I feel foggy, flat and half-switched-off?” It is one of the most-searched questions about SSRIs, and the scale of prescribing explains why. In 2024/25 the NHS Business Services Authority recorded a record 92.6 million antidepressant items dispensed to around 8.89 million people in England, and an estimated 40–60% of SSRI users report some “emotional blunting.” Here is the twist that makes the popular “just boost BDNF” fix collapse: SSRIs generally raise BDNF and hippocampal neurogenesis — that is thought to be part of how they work — so antidepressant fog is not a synapse-deficiency a growth-factor peptide tops up. This 2026 UK review separates medication side effects from depression’s own cognitive symptoms, traces emotional blunting to the reward system, and explains exactly where Dihexa, an HGF/c-Met synaptogenic peptide, actually sits — which is a long way behind a conversation with your prescriber, not in front of it.

Not medical advice — and never a reason to change your medication alone. Dihexa (PNB-0408) is an unscheduled research chemical, not an approved treatment for antidepressant brain fog, emotional blunting or any condition. Do not stop or change an antidepressant without medical advice — abrupt discontinuation can cause withdrawal symptoms and relapse. If you think your medication is causing fog or blunting, the evidence-based route is to talk to your GP or psychiatrist about a dose review, a switch or a planned NICE-guided taper. If you are struggling, contact your GP or, in crisis, call NHS 111 or the Samaritans on 116 123. Read the full legal disclaimer.

Key Findings: Dihexa & SSRI / Antidepressant Brain Fog

  • Prescribing is at record levels: NHSBSA 2024/25 data show 92.6 million antidepressant items dispensed to about 8.89 million identified patients in England — a near-4% year-on-year rise — so side-effect questions affect millions.
  • Emotional blunting is common: an estimated 40–60% of SSRI users report some flattening of positive and negative emotion — one of the leading reasons people want to stop.
  • There is a plausible mechanism: a 2023 University of Cambridge study found the SSRI escitalopram reduced sensitivity to reward and impaired reinforcement learning — how we learn from feedback — offering one explanation for the “numb” feeling.
  • The BDNF logic is backwards here: SSRIs generally increase BDNF and hippocampal neurogenesis via 5-HT1A/5-HT4 signalling — so antidepressant fog is not a BDNF deficiency a synaptogenic peptide refills.
  • Depression itself fogs cognition: a landmark trial found impairments in attention, response inhibition, verbal memory, decision speed and processing that did not fully resolve with acute treatment — meaning fog can be residual depression, not the drug.
  • Disentangling cause is hard: a 2024 analysis found depressive symptoms raised the odds of cognitive impairment and subjective memory problems, which is exactly why blunting and fog need a clinician, not self-diagnosis.
  • PSSD is now formally recognised: post-SSRI sexual dysfunction was added to SNOMED CT in 2024 and is being tracked by UK and other regulators — a reminder these drugs have real, sometimes persistent effects that deserve serious medicine, not grey-market peptides.
  • Stopping must be done properly: NICE NG222 (2022) recommends gradual, prescriber-led tapering — abrupt stopping risks withdrawal and relapse.
  • Why a peptide doesn’t fit: antidepressant fog is a medication-and-illness problem to be solved with the prescriber — not a synapse shortage. Adding an unproven cognitive enhancer risks masking a side effect that should trigger a treatment review.
  • Bottom line: Antidepressant brain fog and emotional blunting are real and common, but they are best addressed by optimising the treatment with a clinician. Dihexa has no human evidence here, the BDNF rationale is largely mistaken, and its biggest real-world risk is delaying the medication review that would actually help.

Antidepressants in 2026: Why This Question Affects Millions

Few medicines touch as many lives as antidepressants. The latest NHS Business Services Authority “Medicines Used in Mental Health” report, published in 2025, recorded 92.6 million antidepressant items dispensed in England in 2024/25 to roughly 8.89 million identified patients — a rise of almost 4% on the previous year and part of a long upward trend. Selective serotonin reuptake inhibitors (SSRIs) such as sertraline, fluoxetine, citalopram and escitalopram, along with SNRIs such as venlafaxine and duloxetine, make up the bulk of that prescribing.

For most people these drugs do an important job: they relieve depression and anxiety that can be disabling and, untreated, are themselves a major cause of foggy, impaired thinking. But a sizeable minority experience side effects that bring them to a search engine, and two of the most-searched are cognitive: a sense of “brain fog” — slowed, cloudy, effortful thinking and patchy memory — and “emotional blunting,” a flattening in which nothing feels quite as sad, but nothing feels quite as good either.

That combination is precisely what draws readers toward nootropics and peptides. If a medication seems to have dialled down clarity and feeling, the intuitive move is to look for something that dials them back up. This review takes that instinct seriously, follows the science of antidepressant cognition down to the receptor, and then asks the question that brings people here: could a synapse-building peptide like Dihexa undo antidepressant fog — or is the honest answer that the fix lives in a conversation with the prescriber?

What “Antidepressant Brain Fog” Actually Means

“Brain fog” is not a medical diagnosis; it is a lay description of slowed thinking, poor concentration, weak short-term memory and mental fatigue. On antidepressants, the experience usually comes in two overlapping forms that are worth separating, because they have different causes and very different solutions.

The first is emotional blunting: a muting of the emotional range — reduced joy, reduced distress, reduced motivation, a feeling of watching life through glass. People often describe it as not caring as much, or struggling to cry or to feel excited. The second is cognitive fog proper: difficulty focusing, holding information in mind, finding words or thinking quickly. The two frequently travel together, which is part of why they get lumped into one complaint — and part of why untangling them matters.

The hardest knot to untie is that depression itself blunts emotion and fogs cognition. Low mood, anhedonia (loss of pleasure) and impaired concentration are core symptoms of depression, not just side effects of its treatment. So a person who still feels flat on medication may be experiencing a drug effect, incompletely treated illness, or both at once. That ambiguity is the single most important fact in this whole topic, and it is the reason the right first step is always clinical assessment, not self-medication.

Emotional Blunting: How Common, and Why It Happens

Emotional blunting is now recognised as one of the most prominent and bothersome effects of long-term antidepressant use. Reviews estimate that somewhere between 40% and 60% of people on SSRIs experience some degree of it, and it is a frequent reason people give for wanting to stop their medication — sometimes even when their mood has objectively improved.

For years the mechanism was unclear. Then, in January 2023, a University of Cambridge study gave healthy volunteers the SSRI escitalopram for several weeks and tested them on tasks measuring how they learned from rewards and punishments. The medicated group showed reduced sensitivity to reinforcement — they were less reactive to feedback that should have shaped their choices. The researchers proposed that by boosting serotonin, SSRIs subtly dampen the reward-learning system, which could explain both the therapeutic calming of negative emotion and the unwanted flattening of positive emotion. In other words, blunting may be the same mechanism that helps, taken a step too far.

This reframing is crucial for the peptide question. Emotional blunting, on this account, is not a sign of damaged or depleted synapses; it is a functional, dose-related shift in a neurotransmitter system that largely reverses when the drug is reduced or changed. That points squarely at the prescriber — a dose reduction, a switch to a different agent, or sometimes augmentation strategies are the levers with evidence behind them. It does not point at building new synapses with a growth factor, because nothing here suggests synapses are missing.

The BDNF Paradox: Why SSRIs Raise the Very Factor Dihexa Mimics

Here the antidepressant story collides head-on with the molecule at the centre of this site. Much of the “Dihexa for antidepressant fog” reasoning rests on a hidden assumption: that antidepressants lower brain-derived neurotrophic factor (BDNF) and starve synapses, so a BDNF-like compound would restore them. The science says almost the opposite.

The dominant neurotrophic hypothesis of antidepressant action is that chronic stress and depression reduce BDNF and hippocampal neurogenesis, and that antidepressants work, over weeks, partly by raising them. A detailed review of serotonin-targeting antidepressants and hippocampal neurogenesis describes how higher synaptic serotonin, acting through 5-HT1A and 5-HT4 receptors, increases CREB activation and BDNF expression and promotes the birth and maturation of new hippocampal neurons — and that blocking this neurogenesis can abolish the behavioural benefit in animals. Far from depleting plasticity, SSRIs are widely understood to enhance it as part of their therapeutic effect.

That detonates the naive case for Dihexa here. If antidepressants are already pushing BDNF-driven plasticity up, then antidepressant brain fog and emotional blunting cannot be a simple “low BDNF” state that a synaptogenic peptide tops up. The blunting appears to be a serotonergic, reward-system effect; the fog is most often residual depression, sedation, poor sleep or a dose issue. None of these is a synapse-count problem, and adding a compound whose entire pitch is “more synaptogenesis than BDNF” is solving an equation the body has, if anything, already over-solved. Our Dihexa vs BDNF page unpacks why the famous “ten million times more potent than BDNF” slogan is a narrow assay result, not a real-world promise — a caution that matters doubly when the BDNF premise itself is wrong.

Is It the Drug or the Depression? Residual Cognitive Impairment

One of the most useful findings in this field is also one of the most sobering. A landmark randomised longitudinal study of cognition in depression found that impairments across five domains — attention, response inhibition, verbal memory, decision speed and information processing — showed little relative improvement with acute antidepressant treatment, even as mood lifted. Cognitive symptoms, in other words, can be a residual feature of depression that lingers after the emotional symptoms recede.

More recent work keeps the picture complicated rather than clean. A 2024 cross-sectional analysis reported that people with depressive symptoms had significantly higher odds of cognitive impairment and subjective memory complaints, and that those on more than one antidepressant, or on tricyclics, reported more subjective memory problems — but such studies cannot prove the direction of cause. People with worse symptoms tend to be on more medication, so heavier prescribing may be a marker of more severe, harder-to-treat illness rather than the source of the fog.

The practical message is humbling for anyone hoping a single supplement will lift the cloud. If a large share of “antidepressant brain fog” is actually under-treated depression, then the intervention with real evidence is to treat the depression more completely — optimising the medication, adding psychological therapy, addressing sleep and exercise — not to layer a research peptide on top of an illness that is still active. Naming the cause correctly is the whole game, and only a clinician can do that with you.

Discontinuation, Withdrawal and PSSD: Stopping Is Its Own Problem

A great deal of antidepressant fog is searched for in the context of coming off the drug, and this is where caution becomes safety-critical. Stopping antidepressants — especially abruptly — can trigger discontinuation (withdrawal) symptoms: dizziness, “brain zaps,” mood swings, insomnia and, yes, a foggy, destabilised feeling. For many people these settle within a couple of weeks, but for some they are more severe and longer-lasting, which is exactly why NICE guideline NG222 (2022) recommends reducing the dose gradually, in steps, in partnership with a prescriber, sometimes over many weeks or longer.

A more contested and serious entity is post-SSRI sexual dysfunction (PSSD) — persistent sexual symptoms, sometimes accompanied by emotional blunting and cognitive complaints, reported by some people after stopping SSRIs or SNRIs. Once dismissed, it is now taken more seriously by regulators: PSSD was added to SNOMED CT in 2024 so it can be formally recorded in medical records, and UK and other drug regulators have begun tracking reports. PSSD remains poorly understood, has no established treatment, and is firmly a matter for specialist medical care.

The relevance to Dihexa is straightforward and important. Withdrawal fog and PSSD are not indications for self-experimentation with an unregulated peptide. They are signals to slow down, work with a doctor, and follow a structured, evidence-based plan. Reaching for a research chemical during a vulnerable taper — or in the hope of reversing a syndrome medicine does not yet understand — adds an unknown to an already difficult situation and could mask the very symptoms a clinician needs to see.

Where Dihexa Enters: The Synaptogenesis Hypothesis

Now the part readers come for. The hopeful case runs like this: depression and chronic stress thin hippocampal synapses; antidepressants are slow and imperfect; so why not use a compound that builds synapses directly and powerfully? On the surface, that is a coherent question — and it is exactly why Dihexa comes up.

Dihexa (PNB-0408) is an orally active, blood-brain-barrier-penetrant peptide that acts as a positive modulator of hepatocyte growth factor (HGF) and its receptor c-Met. In preclinical work — most notably Benoist and colleagues (JPET, 2014) — activating HGF/c-Met drove synaptogenesis, the formation of new dendritic spines and functional synapses, and improved performance in animal memory tasks. The wider HGF/MET system also supports neuronal survival and cerebrovascular health. Our mechanism of action page details the PI-3K/AKT and ERK signalling involved.

The trouble is that the convergence is weaker than it first looks. The therapeutic target in depression is broadly a plasticity deficit that antidepressants already address by raising BDNF and neurogenesis; the side effects people call “antidepressant fog” are mostly a serotonergic reward-system effect (blunting) or residual illness (cognitive fog), neither of which is a synapse shortage. So even granting Dihexa its full animal pharmacology, it is aimed at a problem that, in this context, is largely not the problem. The next section is where that hypothesis meets hard logic — and comes off second best.

Why a Peptide Doesn’t Fix an Antidepressant Problem

The flaw in the synaptogenesis hypothesis here is not the biology of Dihexa; it is the nature of the problem. Antidepressant brain fog and emotional blunting are, overwhelmingly, a treatment-optimisation problem: the dose may be too high, the particular drug may not suit this person, the depression may be incompletely treated, or sleep, alcohol or another condition may be contributing. Every one of those has a route that runs through a prescriber and has evidence behind it — dose review, switching, augmentation, therapy, lifestyle. None is a synapse you can manufacture with a growth-factor peptide.

That mismatch creates a specific and serious danger: masking. Emotional blunting is one of medicine’s most useful signals that a treatment needs adjusting. If a research chemical produced even a modest subjective lift, it could persuade someone to push on with a poorly tolerated regimen rather than have the conversation that would actually fix it — a lower dose, a different molecule, a fuller treatment of the underlying depression. Far from helping, a “cognitive top-up” could entrench a suboptimal prescription and delay real improvement.

There is a sharper safety layer too. Many people experiencing these effects are, by definition, living with depression or anxiety and may be vulnerable, and a large share are also navigating withdrawal or considering stopping their medication — the highest-risk moments for relapse and for impulsive decisions. Encouraging that population to add an unregulated peptide with no human safety data, instead of seeking medical review, is the opposite of care. The general lesson of this site’s depression and anxiety reviews applies in full: when the issue is how a real medical treatment is working, the answer is better medical treatment, not a chemical shortcut.

The Safety Picture and the Stimulant Trap

Beyond the “wrong target” problem, there are concrete reasons for caution that apply to Dihexa regardless of indication. It is an unregulated research chemical with no human safety data: no established dose, no purity guarantees from grey-market suppliers, and no monitoring. Our side effects and risks page sets out the general concerns, including the theoretical worry that a compound which positively modulates the c-Met receptor — a pathway implicated in tumour growth — carries an unquantified long-term risk, particularly for anyone with a personal or family history of cancer.

There is also an interaction unknown that is uniquely relevant here. People reading this are, by definition, taking a serotonergic medication. There is no data on how an HGF/c-Met peptide might interact with SSRIs, SNRIs or other psychotropics, and combining an unstudied compound with a prescribed antidepressant is a gamble no responsible source would encourage. Layer that onto the masking risk above, and the risk–benefit maths looks decisively negative.

Finally, the “push through with a nootropic” mindset is its own trap, familiar from this site’s reviews of modafinil and other stimulants people reach for instead of addressing the root cause. Using a second compound to offset the unwanted effects of the first does not resolve anything; it stacks unknowns. With antidepressants, where the “first compound” is a carefully titrated prescription medicine, that logic is especially misplaced.

The Fosgonimeton Parallel: A Cautionary Tale

Anyone tempted to assume that “activating HGF/c-Met must help cognition” should sit with the story of fosgonimeton (ATH-1017). Developed by Athira Pharma as a small-molecule HGF/c-Met positive modulator — the same mechanism family Dihexa belongs to, but as a genuine clinical candidate with proper manufacturing, dosing and oversight — fosgonimeton was taken into a Phase 3 trial (LIFT-AD) in Alzheimer’s disease. In 2024 it failed to meet its primary endpoint.

The lesson is not that the HGF/c-Met pathway is worthless; it is that a clean mechanism and encouraging animal data are no guarantee of human benefit. A purpose-built drug, taken through rigorous trials, could not show the cognitive improvement its mechanism predicted. Dihexa — an unregulated peptide with no human efficacy trials in any condition, let alone in antidepressant-related cognition — sits far below even that bar. If the well-resourced, carefully run version of this mechanism struggled to prove itself, confident claims for the grey-market version are simply not credible.

Who Should Definitely Not Consider It

Because this topic reaches people who are unwell and sometimes vulnerable, it is worth being explicit about who has the strongest reasons to steer clear of Dihexa entirely. Anyone currently taking an antidepressant should not add it without medical advice, given the complete absence of interaction data and the masking risk. Anyone with a personal or family history of cancer should avoid it given the c-Met/oncology concern. So should anyone who is pregnant, breastfeeding or trying to conceive (see our pregnancy and postpartum review), and anyone under 18.

Above all, nobody should use Dihexa — or any supplement — as a reason to stop or alter a prescribed antidepressant on their own. If the medication seems to be causing fog or blunting, that is information your prescriber needs, not a problem to route around. The meaningful intervention is a clinical review; an unproven research chemical is, for this population, the wrong tool by a wide margin and at a particularly dangerous moment.

Evidence-Based Care: How to Actually Clear Antidepressant Fog

The most useful part of this review is also the least exotic. If you suspect your antidepressant is fogging your thinking or flattening your emotions, the intervention with real evidence behind it is to take that information back to your GP or psychiatrist. Options that genuinely help include a dose review (blunting is often dose-related), a switch to a different antidepressant with a different side-effect profile, treating residual depression more fully with therapy or augmentation, and — if stopping is right — a slow, NICE-guided taper rather than an abrupt halt.

Around that, the unglamorous fundamentals do real work on fog: protect your sleep, which both depression and many antidepressants disrupt; exercise, which supports mood and the brain’s own BDNF; cut alcohol, a potent fog-maker that interacts badly with low mood; and rule out the other common, treatable drivers a GP can check — thyroid problems (see Hashimoto’s and thyroid fog), menopause, and nutritional gaps such as vitamin B12 or iron deficiency.

If, having done all of that, you remain interested in the wider science of cognition and synaptogenesis, our cognitive enhancement overview and research and studies pages set out what is and is not known about Dihexa — honestly, and without pretending the evidence is further along than it is. The order of operations matters: optimise the treatment with your clinician first; everything else is secondary.

The Bottom Line

Antidepressant brain fog and emotional blunting are real, common and worth taking seriously — a record 8.89 million people in England are on these medicines, and 40–60% of SSRI users report some blunting. But the causes are not what the “boost your BDNF” pitch assumes. Blunting looks like a serotonergic, reward-system effect that a 2023 Cambridge study tied to reduced reinforcement learning; the cognitive fog is most often residual depression, sedation, sleep disruption or a dose issue. And critically, SSRIs generally raise BDNF and neurogenesis — so this is not a synapse deficiency for a synaptogenic peptide to refill.

Dihexa is mechanistically interesting, but here the mechanism is aimed at the wrong target. There is no human trial of Dihexa in antidepressant-related cognition, the closest clinical-grade version of its pathway (fosgonimeton) failed its Phase 3, it has no interaction data with the serotonergic drugs readers are taking, and it carries unquantified long-term safety questions. Worse, its most likely real-world effect — making a poorly tolerated regimen feel just bearable — would mask the very signal that should prompt a treatment review. If you take one message from this review, let it be the simplest: the route out of antidepressant fog runs through your prescriber, not through a peptide.

Frequently Asked Questions

Has Dihexa been clinically tested for SSRI or antidepressant brain fog?

No. As of June 2026 there is no registered or completed human clinical trial of Dihexa in antidepressant brain fog, SSRI emotional blunting, residual cognitive impairment or any related condition. The evidence for Dihexa is preclinical (animal and cell) only — see the research and studies page. Self-experiment reports are not clinical evidence.

Do antidepressants cause brain fog and emotional blunting?

Some people on SSRIs and SNRIs report a flattening of emotion, reduced motivation and a foggy, slowed quality of thinking; an estimated 40–60% experience some blunting. A 2023 University of Cambridge study linked SSRIs to reduced reward sensitivity and reinforcement learning. But depression itself blunts emotion and fogs cognition, so the cause must be assessed by a clinician, not self-diagnosed.

If SSRIs lower BDNF, would a BDNF-boosting peptide like Dihexa help?

This is a common misconception. SSRIs generally increase BDNF and hippocampal neurogenesis over weeks — that is thought to be part of how they work, not a deficiency they create. So antidepressant fog is not a low-BDNF state a synaptogenic peptide tops up. Dihexa drives synapse formation via the separate HGF/c-Met pathway in animals (Benoist 2014), but there is no human evidence it helps here and the premise is usually wrong. See Dihexa vs BDNF.

Should I stop my antidepressant to clear the fog?

Not on your own. Stopping abruptly can cause withdrawal (discontinuation) symptoms and risks relapse of depression. NICE guideline NG222 recommends reducing the dose gradually in partnership with your prescriber. If you think the medication is causing blunting or fog, discuss a dose adjustment, a switch or a planned taper with your GP or psychiatrist — never swap it for an unproven research chemical.

What is PSSD, and is it relevant to brain fog?

Post-SSRI sexual dysfunction (PSSD) is a syndrome of persistent sexual and sometimes cognitive and emotional symptoms reported by some people after stopping SSRIs/SNRIs. Regulators now recognise it — it was added to SNOMED CT in 2024 so it can be recorded in medical records. PSSD is still poorly understood, there is no evidence Dihexa treats it, and persistent post-antidepressant symptoms need specialist medical advice.

What actually helps antidepressant brain fog?

Start with your prescriber: a dose review, a switch, or treating residual depression more fully often helps, because untreated depression is itself a major cause of fog. Sleep, exercise, cutting alcohol and checking thyroid or nutritional problems matter too. Cognitive symptoms can also be a residual feature of depression that persists after mood improves. None of this requires a research peptide.

External Authoritative Sources Cited

Editorial statement: This article is part of a rolling 2026 clinical-context review series examining where Dihexa sits in the evidence hierarchy for specific topics. We are not clinicians. This page is for education and is not medical advice, and nothing here should be read as a recommendation to start, stop or change any medication. Antidepressants should only ever be started, changed or stopped under the supervision of a qualified prescriber. If you are struggling with your mental health, contact your GP or, in crisis, call NHS 111 or the Samaritans on 116 123. See the About page for our editorial approach and the disclaimer for legal scope.